The meconium aspiration syndrome (MAS) is a common problem that continues to concern perinatologists and neonatologists. MAS is defined as respiratory distress in an infant born through meconium-stained amniotic fluid (MSAF) whose symptoms cannot be otherwise explained. This disorder may be life threatening, complicated by respiratory failure, pulmonary air leaks and persistent pulmonary hypertension. Approaches to the prevention of MAS have changed over time with collaboration between obstetricians and pediatricians forming the foundations for care. This report details the management of babies delivered with associated MSAF before the accumulation of evidence for best practice through appropriately powered, prospective randomized controlled trials.
Background
Meconium, the fecal material that accumulates in the fetal colon throughout gestation, is a term derived from the Greek mekoni, meaning poppy juice or opium. Commencing with Aristotle's observation of the association between meconium staining of the amniotic fluid and a sleepy state or neonatal depression, obstetricians have been concerned about fetal well being in the presence of meconium-stained amniotic fluid (MSAF). Fetal hypoxic stress may stimulate colonic activity, resulting in the passage of meconium, and also may stimulate fetal gasping movements that result in meconium aspiration.
Meconium is a sterile, thick, black-green, odorless material first observed in the fetal intestine during the third month of gestation. Meconium results from the accumulation of debris, including desquamated cells from the intestine and skin, gastrointestinal mucin, lanugo hair, fatty material from the vernix caseosa, amniotic fluid and intestinal secretions. It comprises 72 to 80% water and contains cholesterol and its precursors, lipids, enzymes including pancreatic phospholipase A2, mucopolysaccharides, protein, bile acids and salts as well as drug metabolites. The black-green color results from bile pigments. When aspirated into the lung, either in the fetus or newly born infant, meconium may stimulate the release of cytokines and other vasoactive substances that lead to cardiovascular and inflammatory responses.
In the fetus, passage of meconium occurs physiologically early in gestation, when it contributes to alkaline phosphatase in amniotic fluid. Abramovich 1 noted that fetal defecation diminishes after 16 weeks and ceases by 20 weeks, concurrent with innervation of the anal sphincter. At that time, the rectum appears to be filled with meconium. From approximately 20 to 34 weeks, fetal passage of meconium was infrequent.
2 Most newborn infants who pass meconium are mature (term). Many are postmature and the babies may exhibit peeling skin, long fingernails and decreased vernix. The vernix, umbilical cord and nails may be meconium stained, depending upon how long the infant has been exposed in utero. In general, nails will become stained after 6 h and vernix after 12 to 14 h of exposure.
The passage of meconium normally occurs within the first 24 to 48 h after birth. However, the passage of fetal meconium, resulting in MSAF, occurs in approximately 8 to 25% of all deliveries, primarily in situations of advanced fetal maturity or fetal stress. Most infants who are delivered with MSAF are beyond the 37 weeks of gestation and meconium rarely appears in amniotic fluid before 32 weeks of gestation. The premature infant lacks 'motilin,' while assists in moving meconium through the lower gastrointestinal track. The meconium aspiration syndrome (MAS), associated with aspiration or perhaps diffusion of meconium into the fetal airways, occurs in about 5% of these infants. 3, 4 Meconium aspiration syndrome is defined as respiratory distress in an infant born through MSAF whose symptoms cannot be otherwise explained. Aspirated meconium can interfere with normal breathing by several mechanisms. They include airway obstruction, chemical irritation, infection and surfactant inactivation (see Figure 1) . When aspirated into fetal lungs, meconium particles mechanically obstruct the small airways. Meconium or the chemical pneumonitis it causes inhibits surfactant function, and inflammation of lung tissue contributes further to small airway obstruction. The chest typically appears barrel-shaped, with an increased anteriorposterior diameter caused by overinflation. Auscultation reveals rales and rhonchi. These signs usually are seen immediately after birth.
The respiratory manifestations include respiratory distress, tachypnea, cyanosis, and air trapping together with reduced pulmonary compliance. Cleary and Wiswell 3 have proposed severity criteria to define MAS: (1) mild MAS is disease that requires less than 40% oxygen for less than 48 h, (2) moderate MAS is disease that requires more than 40% oxygen for more than 48 h with no air leak and (3) severe MAS is disease that requires assisted ventilation for more than 48 h and is often associated with persistent pulmonary hypertension. Of infants in whom the MAS develops, more than 4% die, accounting for 2% of all perinatal deaths.
An estimated 25 000 to 30 000 cases and 1000 deaths related to MAS occur annually in the United States with many more cases in developing countries. However Yoder et al.
5 documented a decline in the incidence of MAS in the United States (from 5.8 to 1.5%Falmost a fourfold reduction) during the period 1990 to 1997, which they attributed to a 33% reduction in the incidence of births at more than 41 weeks' gestation. This probably can be explained by reductions in the number of infants passing meconium (in association with advanced maturity) and in the rate of intrauterine hypoxia (for which the risk is increased in post-term pregnancies).
Acute intrapulmonary meconium contamination induces a concentration-dependent pulmonary hypertensive response, with 15 to 20% of infants with the MAS showing persistent pulmonary hypertension. However, evidence of a long-term process of muscularization of distal pulmonary arterioles in infants with the MAS who died suggests that factors other than meconium aspiration (for example, chronic intrauterine hypoxemia) may contribute to the pulmonary symptoms. 6 Rationale for routine endotracheal intubation to prevent MAS The foundations for routine endotracheal intubation of infants for MSAF was based on what today would be considered entirely anecdotal evidence. Gregory et al. 7 wished to document the prevalence of MSAF, the nature of the MSAF (thick or watery, thick but still liquid, particulate) and the incidence of respiratory distress when there was meconium present. In a prospective collection of data they reported MSAF in 8.8% of 1000 consecutive newborn infants over a 6 month time period. They aspirated the upper and lower airways as soon as possible 'sometimes before the first breath' in 80 of the 88 infants with MSAF. 7 If the trachea contained meconium, intubation and suctioning were repeated until the airway had been cleared. Fifty-seven infants had meconium in their mouth, 62 had meconium in the stomach and 8 had meconium in the trachea but none in the mouth or larynx. Half of the infants with meconium in the airway (23 of 46) had abnormal chest X-rays and 16 (70%) of these were symptomatic. They subsequently compared incidence of air leaks in 35 hospitalized infants with MAS from their institution (2 of 35; 6%) with 15 outborn infants with MAS including 6 of the 15 (40%) with air leaks. They concluded that 'all infants born through thick, particulate or 'pea soup' meconium should have their trachea aspirated immediately after birth by the most experienced person in the delivery room and receive thoracic physical therapy and postural drainage for the first 8 h of life, if the meconium is recovered from the trachea and/or the chest X-ray is consistent with aspiration.' Ting and Brady 8 a year later following a retrospective chart review noted that of 97 infants with thick meconium who received endotracheal suctioning at birth, 27 became symptomatic and only one died. On the other hand, 28 infants with thick meconium who were not suctioned, 16 became symptomatic and 7 died. Soon thereafter Carson et al. 9 published their combined obstetric and pediatric approach to prevent MAS. In a study originally intended to examine the effectiveness of pulmonary lavage for MAS, they performed routine intrapartum pharyngeal suctioning with a DeLee catheter with the infants head on the perineum, before the onset of respirations, thereafter inspecting the larynx when the baby delivered and intubating and suctioning if meconium was present. Their treatment group was compared to historical controls, MAS occurred in 1 of 273 (0.4%) with routine suctioning and 18 of 947 (1.9%) (P ¼ 0.07) in the non-suctioned group. They noted that routine suctioning of the trachea under direct vision after delivery is rarely necessary but should be performed if meconium is visualized at the vocal cords, and tracheobronchial lavage with saline may add to the respiratory morbidity. They indicated that 'No deaths or severe cases of MAS have occurred since institution of the obstetric suctioning procedure' and concluded that 'routine intrapartum pharyngeal suctioning with a DeLee catheter of infants with meconium staining has significantly reduced the incidence and severity of MAS' despite a P-value not supporting such a conclusion.
On the basis of these studies by Gregory,  7 Ting  8 and Carson,   9 the commonest approach to MSAF, whether thick, watery or particulate, was for the obstetrician to immediately suction the nasopharynx as soon as the head appeared on the perineum. Thereafter, visualization of the cords by direct laryngoscopy and suctioning of the trachea through the endotracheal tube if meconium was detected was the routine adopted at most centers. This was performed before stimulation of the infant or administration of positive pressure ventilation. This approach remained the standard of care until challenged by a series of prospective randomized trials.
Corticosteroids for MAS
Yeh et al. 10 evaluated the efficacy of glucocorticoids in the treatment of infants with MAS. Using a 'double blind' technique they randomized 35 infants with MAS to hydrocortisone or a lactose placebo. No significant differences in arterial PO 2 , PCO 2 , pH, A-aDO 2 gradients, requirement for assisted ventilation, or in survival were observed between the groups. In the placebo group, a significant decrease in respiratory distress score occurred at 48 to 72 h of age (P<0.01); in hydrocortisone-treated infants, it was seen only after 72 h. The infants in the steroid group took a significantly longer period of time to wean to room air than those in the control group (68.9 ± 9.6 vs 36.6 ± 6.9 h) (P<0.01). They concluded that hydrocortisone is not recommended for the treatment of MAS.
MAS and pulmonary hypertension
Pulmonary hypertension was a significant comorbidity in infants with MAS and frequently the cause of death. The management of pulmonary hypertension was haphazard and the outcomes unpredictable. Fox et al. 11 reported on 10 patients clinically diagnosed as having perinatal aspiration syndromes together with pulmonary hypertension. These infants were either term or postmature babies and at catheterization had the following characteristics: (1) systemic or supra-systemic levels of pulmonary artery pressure (PAP) (range, 50 to 117 mm Hg); (2) a degree of pulmonary hypertension not related to the degree of aspiration evident on chest roentgenograms; (3) evidence of right-to-left shunting at the ductal or foramen ovale level and (4) sustained severe hypoxemia despite 100% inspired oxygen concentration. Indwelling pulmonary artery catheters were used for continuous monitoring of PAP in these 10 infants with severe persistent pulmonary hypertension of the newborn. The labile nature of PAP, with changes up to 50 mm Hg, was documented. PAP in the eight infants with supra-systemic pulmonary hypertension was analyzed at the time of maximum decrease in pressure (mean 36.1 mm Hg) and physiologic measurements were compared over an 8-h period.
During the study period when the infants were hyperventilated, as the PaCO 2 decreased from 48.9 to 28.3 mm Hg (P<0.02), the mean PAP decreased by 36 mm Hg (P<0.001) to sub-systemic pressure levels, and the mean alveolar/arterial oxygen difference decreased by 146 mm Hg (P<0.001). Following the decrease in PAP, patients were mechanically ventilated to maintain PaCO 2 in the range of 25 to 30 mm Hg until pulmonary hypertension gradually resolved in the six survivors. On the basis of this small uncontrolled study, hyperventilation to lower pCO 2 levels became the standard of care, and in light of present knowledge probably contributed to a number of deaf survivors.
Extracorporeal membrane oxygenation and MAS
The history of the introduction of extracorporeal membrane oxygenation (ECMO) into neonatal perinatal medicine is closely aligned with the management of MAS. Bartlett et al.
12 documented 16 moribund newborn infants with respiratory failure who were treated with ECMO for 1 to 8 days. Their diagnoses and outcomes included respiratory distress syndrome, four patients (two improved, one survived); MAS, eight patients (four improved, three survived); persistent fetal circulation (some with diaphragmatic hernia), four patients (three improved, two survived). Intracranial bleeding occurred in 43% accounting for most of the deaths. In a parallel series of 21 infants treated with conventional ventilator therapy, the mortality rate was 90% and intracranial bleeding occurred in 57%. They modestly concluded that ECMO provided life support and gains time in newborn respiratory failure. In high mortality risk infants, the rate of survival is higher and that of intracranial bleeding is lower with ECMO than with optimal ventilator management. So dawned the ECMO era, and ultimately the survival of many moribund infants with pulmonary hypertension and respiratory failure, including those with MAS. Indeed, in the ECMO registry, the highest survival rates (>90%) were seen in the patients with MAS who qualified for ECMO. With the evidence-based approach to prevention of MAS and the initiation of better less-invasive therapies, including inhaled nitric oxide, surfactant therapy, surfactant lavage and various modes of mechanical ventilation, including high-frequency ventilation, it is rare for an infant to require ECMO for MAS. [13] [14] [15] [16] Evidence-based practice to prevent MAS On the basis of the evidence from non-randomized studies, [6] [7] [8] to reduce the incidence and severity of MAS the recommendation was to intubate and suction all babies born through thick meconium. However, for term babies who are vigorous at birth endotracheal intubation may be both difficult and unnecessary. This concept of routine intubation was challenged first by Faciglia using a concurrent observational study. 17, 18 He showed no differences in outcome with and without routine intubation. Linder et al. 19 in a prospective controlled trial, perhaps inadequately randomized, assessed the need for intubation of vigorous term meconiumstained infants. Of 572 infants, meconium-stained infants, delivered vaginally, with 1-min Apgar score of 9 or 10, none of 264 expectantly managed infants developed MAS and 2 of 308 intubated infants developed MAS. They concluded that intubation may be superfluous in a vigorous infant born through MSAF and practice started to change. A decade later in international prospective, randomized, controlled trial assessing need for intubation of apparently vigorous meconium-stained infants, Wiswell et al. 20 enrolled 2094 babies born with MSAF to either intubation and suctioning or to expectant management. They found no significant differences in either MAS or any respiratory disorders supporting the concept that it was not necessary to intubate vigorous term infants irrespective of the nature of the MSAF (thick or thin). Halliday 21 accumulated four randomized controlled trials of endotracheal intubation at birth in vigorous term meconium-stained babies, which were identified. Meta-analysis of these trials does not support routine use of endotracheal intubation at birth in vigorous meconium-stained babies to reduce mortality, MAS, other respiratory symptoms or disorders, pneumothorax, oxygen need, stridor, HIE and convulsions. However, the event rates of many of these outcomes is low in the reported trials making reliable estimates of treatment effect impossible.
Vain et al. 22 finally shattered all the anecdotal data when they reported on their prospective randomized trial that routine intrapartum oropharyngeal and nasopharyngeal suctioning of term-gestation infants born through MSAF does not prevent MAS.
Amnioninfusion
Amnioinfusion has been advocated as a technique to reduce the incidence of meconium aspiration and to improve neonatal outcome. However, meconium passage may predate labor so that a large proportion of women with MSAF have infants with meconium in the trachea or bronchioles before meconium passage has been noted clinically and before amnioinfusion can be performed. 23 Fraser et al. 24 reported that for women in labor who have thick meconium staining of the amniotic fluid, amnioinfusion did not reduce the risk of moderate or severe MAS, perinatal death, or other major maternal or neonatal disorders. 25 Xu et al. 26 summarized the evidence for the use of amnioinfusion to prevent MAS. They concluded that in clinical settings with standard peripartum surveillance, the evidence does not support the use of amnioinfusion for MSAF. In settings with limited peripartum surveillance, where complications of MSAF are common, amnioinfusion appears to reduce the risk of MAS. As always they noted that further studies were needed.
Long-term consequences
The initial follow-up report on follow-up of MAS by Marshall et al. 27 in 1978 included a 1-year cohort of 17 patients, representing 3.7% of all admissions to their unit. Four patients (23.5%) died of acute respiratory failure and two patients with MAS, and persistence of the fetal circulation required cardiac catheterization to exclude cyanotic congenital heart disease. None of the survivors had persistent chronic lung disease but two of three patients with MAS and seizures had significant psychomotor retardation at follow-up examination. The current data indicate that there is an increased prevalence of asthmatic symptoms and abnormal bronchial reactivity among survivors of the MAS.
Conclusion
Meconium aspiration syndrome remains a challenging condition most notably in developing countries. In the USA avoidance of post-term pregnancies, improved intrapartum monitoring and amnioinfusion have dramatically reduced the incidence of MAS. Whereas there is inconclusive evidence as to the optimal ventilator strategy for MAS, surfactant replacement therapy has been beneficial and surfactant lavage is still being explored. Inhaled nitric oxide has significantly enhanced the treatment of pulmonary hypertension and substantially reduced the need for ECMO. Despite optimal perinatal management, infants born through MSAF may still develop MAS and have morbid or even fatal outcomes.
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